share_log

Stifel Upgrades C4 Therapeutics to Buy, Raises Price Target to $12

Stifel Upgrades C4 Therapeutics to Buy, Raises Price Target to $12

Stifel 將 C4 Therapeutics 升級爲收購,將目標股價提高至12美元
Benzinga ·  2023/12/13 04:16

Stifel analyst Bradley Canino upgrades C4 Therapeutics (NASDAQ:CCCC) from Hold to Buy and raises the price target from $2 to $12.

Stifel分析師布拉德利·卡尼諾將C4 Therapeutics(納斯達克股票代碼:CCCC)從持有上調至買入,並將目標股價從2美元上調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論